Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.54 |
| ▸ | YAP1 | P46937 | 3/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | BCL9 | O00512 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425979 | 0.90 | YAP1 (0.49) | MGLLYAP1OPRD1OPRK1GPR119 | |
| SCHEMBL2425943 | 0.88 | MGLL (0.53) | MGLLALDH1A1 | |
| SCHEMBL3347944 | 0.88 | MGLL (0.53) | MGLLALDH1A1 | |
| SCHEMBL2339621 | 0.86 | PRMT5 (0.49) | MGLLYAP1OPRD1OPRK1GPR119 | |
| SCHEMBL22880757 | 0.85 | MGLL (0.52) | MGLLOPRD1OPRK1GPR119TACR1 | |
| SCHEMBL18418311 | 0.85 | MGLL (0.52) | MGLLOPRD1OPRK1GPR119TACR1 | |
| SCHEMBL2424183 | 0.84 | MGLL (0.55) | MGLLGPR119TACR1IDO1 | |
| SCHEMBL2423590 | 0.84 | MGLL (0.55) | MGLLGPR119TACR1IDO1 | |
| SCHEMBL2427027 | 0.84 | MGLL (0.55) | MGLLGPR119TACR1IDO1 | |
| SCHEMBL2429904 | 0.84 | MGLL (0.75) | MGLLGPR119IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367830-A1 | 1-OXA-8-AZASPIRO [4, 5] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | Pfizer Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
| WO-2010058318-A1 | 1-OXA-8-AZASPIRO [4, 5 ] DECANE- 8 -CARBOXAMIDE COMPOUNDS AS FAAH INHIBITORS | PFIZER INC. (US) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230493-A1 | 1-OXA-8-Azaspiro [4,5] Decabe-8-Carboxamide Compounds as FAAH Inhibitors | FAAH, FAAH2, FFAR1 | MGLL 246/4885YAP1 4289/4885OPRD1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.